Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 203-441-9 | CAS number: 106-91-2
Basic toxicokinetics
Administrative data
- Endpoint:
- basic toxicokinetics in vivo
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
Data source
Referenceopen allclose all
- Title:
- No information
- Author:
- Shi Tao et al.
- Year:
- 1 988
- Bibliographic source:
- Shi Tao et al., Zhongguo Yaolixue Yu Dulixue Zazhi, 2(3), 226-31 (1988).
- Title:
- No information
- Author:
- OECD
- Year:
- 1 999
- Bibliographic source:
- OECD SIDS for glycidyl methacrylate, December 1999
Materials and methods
- GLP compliance:
- not specified
Test material
- Reference substance name:
- 2,3-epoxypropyl methacrylate
- EC Number:
- 203-441-9
- EC Name:
- 2,3-epoxypropyl methacrylate
- Cas Number:
- 106-91-2
- Molecular formula:
- C7H10O3
- IUPAC Name:
- oxiran-2-ylmethyl methacrylate
Constituent 1
Test animals
- Species:
- rabbit
Administration / exposure
- Route of administration:
- other: intra-venous and subcutaneous
Doses / concentrations
- Remarks:
- Doses / Concentrations:
intravenous: 200 mg/kg
subcutaneous: 800 mg/kg
Results and discussion
Any other information on results incl. tables
Toxicokinetics of glycidyl methacrylate was investigated in rabbits. After an intravenous injection at 200 mg/kg, the concentration-time curve of this chemical could exactly fit the two-compartment open model, and over 95 % of the parent compound had disappeared from the blood within 10 minutes. Following a subcutaneous injection at 800 mg/kg, the toxicokinetics appeared to fit a first-order absorption one-compartment open model. This chemical was metabolized by a first-order process in incubation with whole blood, plasma, erythrocyte suspension, and homogenates of brain, heart, liver, lung, spleen, kidney, small intestine, and muscle. The highest rate of elimination had been found in blood and liver homogenate. The subcutaneous co-administration of tri-o-cresyl-phosphate (an carboxylesterase inhibitor) with this chemical resulted in about a tenfold increase in the maximum blood concentrations of this chemical, compared to those of animals dosed with this chemical alone. In vitro,elimination rate could be also decreased by tri-o-cresyl
phosphate.Applicant's summary and conclusion
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
